A 65-year-old man from Bangalore presents with hematuria and is found to have a 5 cm mass in the left kidney on contrast-enhanced CT. There is no evidence of renal vein invasion, and staging CT chest/abdomen shows no distant metastases. Biopsy confirms clear cell renal cell carcinoma (RCC), Fuhrman grade 3. What is the most appropriate next step in management?

Explanation

## Management of Localized Renal Cell Carcinoma **Key Point:** For localized RCC without distant metastases, surgical resection is the only curative approach. The choice between radical and partial nephrectomy depends on tumor size, grade, and renal function. ### Why Radical Nephrectomy Is Indicated **High-Yield:** This patient has: - **T2, N0, M0** disease (stage III by AJCC) - **5 cm tumor** (exceeds the 4 cm threshold for nephron-sparing surgery) - **Fuhrman grade 3** (high-grade, aggressive) - **No renal vein invasion** **Indications for Radical Nephrectomy:** | Feature | Radical Nephrectomy | Partial Nephrectomy | |---------|-------------------|---------------------| | **Tumor size** | >4 cm | ≤4 cm (or select T1b) | | **Grade** | High-grade (3–4) | Low-grade (1–2) | | **Renal function** | Normal or one kidney | Solitary kidney, CKD | | **Vascular invasion** | Present | Absent | | **Margin adequacy** | Easier to achieve | Requires careful dissection | **Clinical Pearl:** Partial nephrectomy is preferred for **T1a** (≤4 cm) tumors to preserve renal function, but this patient's **5 cm, grade 3** tumor is best managed with radical nephrectomy to ensure adequate oncologic margins and regional lymph node assessment. ### Treatment Algorithm for Localized RCC ```mermaid flowchart TD A[Localized RCC<br/>T1-4, N0, M0]:::outcome --> B{Tumor size?}:::decision B -->|≤4 cm<br/>T1a| C{Solitary kidney<br/>or CKD?}:::decision B -->|>4 cm<br/>T1b-T4| D[Radical nephrectomy]:::action C -->|Yes| E[Partial nephrectomy]:::action C -->|No| F{Grade and<br/>vascular invasion?}:::decision F -->|Low-grade, no invasion| E F -->|High-grade or invasion| D D --> G[Regional lymph node dissection]:::action E --> H[Nephron-sparing approach]:::action G --> I{Adjuvant therapy<br/>needed?}:::decision I -->|High-risk features| J[Consider targeted therapy<br/>sunitinib/sorafenib]:::action I -->|Standard risk| K[Surveillance]:::action ``` **Mnemonic:** **GRADE-RCC** = **G**reat tumor (>4 cm) → **R**adical nephrectomy; **A**denocarcinoma grade 3–4 → **D**efine margins; **E**arly stage, small → **R**enal-sparing; **C**lear cell type → **C**urative surgery first. **Warning:** Systemic therapy (sunitinib, sorafenib) is reserved for metastatic or unresectable disease. It is not a substitute for surgery in localized disease. [cite:Robbins 10e Ch 18]